...Sadik Etka Bayramoglu; Nihat Sayin; Ibrahim Kocak Introduction: The aim of this study was to investigate the relationship between the location of retinal vascularization and plus severity with re-treatment rates in intravitreal bevacizumab (IVB)-treated eyes. Methods: For this retrospective...

..., no significant difference was observed in all six genetic models. Ranibizumab and bevacizumab had similar efficacy; however, conbercept was more effective in homozygous genotypes. The literature indicated that TT and TC genotypes and T allele were associated with a better functional response, while the CC...

..., the effects of long-term and repeated treatment on these cells are scarce. In this study, we have investigated the effects of anti-VEGF treatment (bevacizumab and aflibercept) after long-term, repeated treatment on uptake, storage, and subcellular localization. Methods: Experiments were conducted in primary...

...Hung-Ju Chen; Chin Lin; Cho-Hao Lee; Yi-Hao Chen Aim: The objective of this study was to evaluate the efficacy and safety of bevacizumab combined with antimetabolite as an adjunctive therapy in primary trabeculectomy for glaucoma. Materials and Methods: PubMed, Cochrane Library, and EMBASE were...

... population. Methods: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the number of injections over 1 year of follow-up were correlated with CFH...

...Natàlia Vilà; Jacqueline Coblentz; Carlos Moreira-Neto; Vasco Bravo-Filho; Pablo Zoroquiain; Miguel N. Burnier Jr. Purpose: To determine whether pretreatment of retinal pigmented epithelial (RPE) cells with lutein can affect the response of cells to bevacizumab therapy. Methods: One human RPE cell...

...Christophe Chiquet; Alain M. Bron; Morgane Straub; Caroline Dupuy; Rodica Isaico; Florent Aptel; Catherine Creuzot-Garcher Purpose: To compare the visual and anatomical outcomes of patients with macular oedema secondary to retinal vein occlusion (RVO) after a switch from bevacizumab to intravitreal...

...Flavio Mac Cord Medina; Augusto Alves Lopes da Motta; Walter Y. Takahashi; Pedro Carlos Carricondo; Mario Martins dos Santos Motta; Monica B. Melo; Jose Paulo C. Vasconcellos Purpose: To compare the functional and morphological response to the initial intravitreal (IVT) injection of bevacizumab...

...Rony C. Preti; Lisa M.V. Ramirez; Sergio L.G. Pimentel; Yoshitaka Nakashima; Cleide G. Machado; David E. Pelayes; Mario L.R. Monteiro; Walter Y. Takahashi Purpose: To evaluate the results of intravitreal bevacizumab (IVB) injection on contrast sensitivity (CS), best-corrected visual acuity (BCVA...

...Carlos E. Veloso; Raul N. Vianna; David E. Pelayes; Márcio B. Nehemy Background/Aims: The aim of this paper is to report the treatment of type 2 nonproliferative idiopathic macular telangiectasia (IMT) with intravitreal bevacizumab (IVB). Methods: Retrospective case series of 10 eyes of 5 patients...

...Iichiro Sugita; Masahiko Yoneda; Masayoshi Iwaki; Masahiro Zako Background: Differences in the efficacy of bevacizumab, an antivascular endothelial growth factor (VEGF) agent, against retinopathy with neovascularization when injected into the vitreous cavity of vitrectomized and nonvitrectomized...

...Abdelrahman G. Salman Purpose: To evaluate the efficacy and safety of intrasilicone injection of bevacizumab for the treatment of iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Methods: Bevacizumab 1.25 mg/0.05 ml was injected into silicone oil in 15 eyes of 11...

... endothelial growth factor Ranibizumab Bevacizumab Pegaptanib VEGF Trap-Eye Diabetic retinopathy is the most frequent retinal vascular disorder and is found in about 40% of diabetic patients 40 years and older [ 1, 2, 3 ]. The VEGF Trap-Eye (Eylea, Regeneron/Bayer) is a 115-kDa recombinant...

... ] reported a patient with coexisting primary choroidal melanoma (treated with radiation who later developed radiation maculopathy) and metastatic colorectal cancer. When systemic bevacizumab (Avastin®, 5 mg/kg) was added to chemotherapy, there was complete resolution of the macular edema and subretinal fluid...

...Veysi Öner; Cem Küçükerdönmez; Yonca Aydın Akova; Aysel Çolak; Aylin Karalezli Aims: To evaluate and compare the inhibitory effects of topical and subconjunctival bevacizumab on corneal neovascularization in a rat model. Methods: Twenty corneas of 20 rats were chemically cauterized with silver...

...Franziska Drechsler; Patricia Köferl; Margrit Hollborn; Peter Wiedemann; Andreas Bringmann; Leon Kohen; Matus Rehak Purpose: To determine the effect of intravitreal bevacizumab and anti-vascular endothelial growth factor (VEGF) antibodies on the gene expression in the neural retina in a rat model...

...Yuichi Niwa; Osamu Sawada; Taichiro Miyake; Masasi Kakinoki; Tomoko Sawada; Hajime Kawamura; Masahito Ohji Aim: To compare the effects of one intravitreal bevacizumab (IVB) injection with three monthly injections for myopic choroidal neovascularization. Methods: Group A included 13 patients treated...

...David Cia; Jacques Cluzel; Nathalie Jacquemot; Michel Doly Aim: To evaluate the in vitro effects of bevacizumab (Avastin®) on the electroretinogram (ERG) in rats using a model of isolated perfused retina ERG recording. Methods: Retinas were isolated from rat eyes and placed in a chamber...

...Lan-Hsin Chuang; Wei-Chi Wu; Ling Yeung; Nan-Kai Wang; Yih-Shiou Hwang; Kuan-Jen Chen; Jane Zea-Chin Kuo; Chi-Chun Lai Aim: To compare the serum concentration of bevacizumab after intravitreal injection of bevacizumab (IVB) in an experimental model of branch retinal vein occlusion (BRVO...

...Mohamad Amr Salah Eddin Abdelhakim; Tamer A. Macky; Khaled Abdel Galil Mansour; Hassan Ali Mortada Purpose: To evaluate the role of preoperative intravitreal bevacizumab as an adjunct to vitrectomy in diabetic eye disease. Methods: Twenty eyes of 18 patients were recruited and underwent a single...